Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 14/20 | 0.58 |
| ▸ | EGFR | P00533 | 11/20 | 0.58 |
| ▸ | JAK3 | P52333 | 4/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.57 |
| ▸ | ITK | Q08881 | 3/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | BLK | P51451 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | LYN | P07948 | 1/20 | 0.49 |
| ▸ | TEC | P42680 | 1/20 | 0.49 |
| ▸ | TXK | P42681 | 1/20 | 0.49 |
| ▸ | BMX | P51813 | 1/20 | 0.49 |
| ▸ | CD69 | Q07108 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6484825 | 0.92 | EGFR (0.66) | BTKEGFRJAK3ERBB2ITK | |
| SCHEMBL6492634 | 0.87 | EGFR (0.54) | BTKEGFRJAK3ERBB2JAK2 | |
| SCHEMBL6497404 | 0.83 | BTK (0.57) | BTKEGFRJAK3ERBB2ITK | |
| SCHEMBL6482765 | 0.82 | JAK3 (0.57) | BTKEGFRJAK3ITKSRC | |
| SCHEMBL6482330 | 0.81 | EGFR (0.62) | BTKEGFRJAK3ERBB2ITK | |
| SCHEMBL30423295 | 0.80 | EGFR (0.75) | BTKEGFRJAK3ERBB2ITK | |
| SCHEMBL28400978 | 0.80 | EGFR (0.75) | BTKEGFRJAK3ERBB2ITK | |
| SCHEMBL6496345 | 0.79 | ERBB2 (0.58) | BTKEGFRJAK3ERBB2ITK | |
| SCHEMBL6483467 | 0.78 | ERBB2 (0.58) | BTKEGFRJAK3ERBB2ITK | |
| SCHEMBL13165499 | 0.76 | BTK (0.79) | BTKEGFRJAK3ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6881737-B2 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. (US) | 2005-04-19 | — | — | US | claimed |
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. | 2003-07-24 | — | — | US | claimed |
| US-6881737-B2 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. (US) | 2005-04-19 | — | — | US | disclosed |
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | PKD1, PKD2, GLS | BTK 204/4885EGFR 228/4885JAK3 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.